Acepodia secures FDA clearance to begin Phase I ACE723 trial

Phase 1ACE723Positive

AI Analysis

Summary

Acepodia has received FDA clearance for an IND application to initiate a Phase 1 trial of ACE723 in patients with unresectable or metastatic hepatocellular carcinoma.

Clinical Trial Data

Phase

Phase 1

Outcome Details

FDA clearance for IND application granted

Importance:5/10

Sentiment:

0.70

FDA clearanceIND approvalPhase 1 trialhepatocellular carcinomaoncology

Related Companies

$TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on September 7, 2026 9:29 AM

Read Original